Mirum Pharmaceuticals to Share Financial Insights Soon
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is gearing up to unveil its financial results for the third quarter of 2024. The company has set the stage for an important conference call where it will discuss the financial outcomes and notable corporate developments.
Conference Call Details
For those interested, the conference call will take place on November 12, 2024, at 8:30 a.m. ET (5:30 a.m. PT). Participants can dial in via the U.S./Toll-Free number at + 1 833 470 1428 or the International number at + 1 404 975 4839, using the passcode 749358.
Webcast Access Available
In addition to the audio call, Mirum will offer an online webcast option. You can join by navigating to the Events & Presentations section on Mirum's official website, where a replay will be accessible for 30 days following the event.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals is dedicated to innovating treatments for rare diseases that impact both children and adults. Currently, the company has three approved therapies: LIVMARLI (maralixibat) oral solution, CHOLBAM (cholic acid) capsules, and CHENODAL (chenodiol) tablets.
Key Therapies Explained
LIVMARLI is pivotal in treating two rare liver diseases in patients with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). This drug has received approvals across various age groups and continues to assist patients in need. It is worth mentioning that Mirum is also pursuing a Phase 3 study, EXPAND, to broaden LIVMARLI's application in other cholestatic pruritus cases.
CHOLBAM serves as an FDA-approved treatment aimed at bile acid synthesis disorders stemming from single enzyme deficiencies. This therapy is aimed at individuals exhibiting liver disease symptoms. On the other hand, CHENODAL has been identified by the FDA for its necessity in treating cerebrotendinous xanthomatosis (CTX). Mirum's commitment to treating these conditions makes it a key player in the biopharmaceutical field.
Exploring Future Opportunities
Mirum has an encouraging late-stage pipeline, which features investigational therapies for challenging liver diseases. The compound Volixibat, an IBAT inhibitor, is currently being studied in significant registrational trials, including the VISTAS study for primary sclerosing cholangitis (PSC) and the VANTAGE study targeting primary biliary cholangitis.
This product has already been granted a Breakthrough Therapy Designation, underscoring its potential impact on patients suffering from cholestatic pruritus related to PBC. Furthermore, Chenodiol is undergoing evaluation in the Phase 3 RESTORE clinical trial to address CTX, with promising topline results announced recently.
Mirum's Online Presence and Community Engagement
The company encourages individuals to learn more about its innovative therapies by visiting mirumpharma.com and engaging on various social media platforms like Facebook, LinkedIn, Instagram, and Twitter. Through these channels, Mirum shares important updates and connects with its community, fostering a supportive environment.
Frequently Asked Questions
1. When will Mirum Pharmaceuticals announce its financial results?
Mirum Pharmaceuticals will announce its third-quarter financial results on November 12, 2024.
2. How can I join the conference call?
You can join the conference call by dialing U.S./Toll-Free at + 1 833 470 1428 or Internationally at + 1 404 975 4839 using the passcode 749358.
3. Is there a webcast available for the conference call?
Yes, there will be a webcast available, and you can access it by visiting the Events & Presentations section on Mirum's website.
4. What are the approved treatments offered by Mirum?
Mirum has three approved medications: LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CHENODAL (chenodiol).
5. What is the focus of Mirum Pharmaceuticals?
The company focuses on developing treatments for rare diseases that affect both children and adults, particularly those related to liver conditions.
